{"result": "(\"entity\"<|>CREATINE<|>ORGANIZATION<|>Creatine is a supplement that was tested for its efficacy in treating mitochondrial diseases but showed no benefit in the studied patients)\n##\n(\"entity\"<|>INSULIN<|>ORGANIZATION<|>Insulin is a medication added to the patient's treatment regimen to manage elevated blood glucose levels)\n##\n(\"entity\"<|>DIABETES<|>EVENT<|>The patient has mitochondrial diabetes, which complicates their treatment and requires careful management)\n##\n(\"entity\"<|>NUTRITIONAL SUPPLEMENTS<|>ORGANIZATION<|>Nutritional supplements were prescribed to the patient to stabilize weight and address caloric deficiency)\n##\n(\"entity\"<|>PLATELET INFUSION<|>EVENT<|>Platelet infusion is a treatment that was considered for the patient but was found to be only temporarily effective)\n##\n(\"relationship\"<|>PATIENT<|>CREATINE<|>Creatine was tested on the patient but found to be ineffective after four weeks of treatment<|>5)\n##\n(\"relationship\"<|>PATIENT<|>INSULIN<|>Insulin was added to the patient's treatment plan to help control high blood sugar levels<|>7)\n##\n(\"relationship\"<|>PATIENT<|>DIABETES<|>The patient suffers from mitochondrial diabetes, which affects their overall treatment strategy<|>8)\n##\n(\"relationship\"<|>PATIENT<|>NUTRITIONAL SUPPLEMENTS<|>Nutritional supplements were prescribed to the patient to help with caloric intake and weight stabilization<|>6)\n##\n(\"relationship\"<|>PATIENT<|>PLATELET INFUSION<|>Platelet infusion was considered as a treatment option for the patient but was ultimately deemed ineffective<|>4)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 16 pacientes con en-\nfermedades mitocondriales no encontró ningún beneficio tras 4 semanas de tratamien-\nto con altas dosis de creatina7  . Dada la evidencia de al menos un ensayo controlado\nde un beneficio modesto y seguridad en relación con efectos adversos se recomienda\na dosis de 10 g durante las primeras dos semanas seguidos de 4 g de mantenimien-\nto. Sin embargo, los calambres suelen ser un problema con altas dosis por lo que se\nrecomienda comenzar con 4.5 g al día dividido en tres dosis y titular según tolerancia\ncon un máximo de 10 g al día. En nuestro paciente no se instauró tratamiento dada la\nneuropatía severa de base que presentaba. En relación al tratamiento con L-carnitina\nno hay estudios controlados en pacientes con enfermedad mitocondrial. Sin embargo,\nse ha visto beneficiosa en pacientes con deficiencia sistémica primaria de carnitina. Se\nsugiere el tratamiento con carnitina ya que es seguro y corrige el déficit subyacente de\ncarnitina en estos pacientes. Se recomienda una dosis de 1000 mg al día por la mañana8 .\n         Los estudios publicados en pacientes con MNGIE tratados con diálisis o infusión\nde plaquetas de donantes sanos como tratamiento para disminuir los niveles de timi-\ndina y deoxiuridina de la circulación, y parcialmente restituir la actividad de la timidin\nfosforilasa, son poco esperanzadores ya que ambos tratamientos tiene la limitación de\nser transitorios. Los tratamientos de reposición enzimáticos están aún en desarrollo.\nEl trasplante alogénico de células hematopoyéticas ofrece la posibilidad de corregir\nel déficit enzimático, con el propósito de corregir los daños metabólicos al restaurar\nla actividad de la timidin fosforilasa, disminuyendo las concentraciones plasmáticas\nde timidina y deoxiuridina. Más de diez pacientes con MNGIE han sido tratados con\ntrasplante de células hematopoyéticas9 . Sin embargo, este tratamiento presenta un\nalto porcentaje de mortalidad de hasta el 70%. El trasplante hepático ortotópico es\nuna buena alternativa en los pacientes con MNGIE dado que el hígado es una fuente\nimportante de timidin fosforilasa. Presenta menos riesgo de morbi-mortalidad que el\ntrasplante de células hematopoyéticas, efecto duradero a diferencia de la diálisis y la\ninfusión de plaquetas, y es una opción terapéutica a considerar en relación a la mejoría\nde la supervivencia en este tipo de pacientes10 .\n                                                                                            69\n---\n             El paciente que comentamos presentaba una situación de desnutrición calórica\n    importante, junto con síntomas de dismotilidad intestinal con plenitud postprandial y\n    diarrea. Recibió recomendaciones dietéticas y se pautaron suplementos nutricionales\n    orales específicos de diabetes, que aportaban 900 kcal al día, consiguiendo estabilizar\n    peso. Por otra parte, se inició tratamiento con antidiabéticos orales. Hay que tener en\n    cuenta que, al presentar el paciente una diabetes mitocondrial, hay que evitar el tra-\n    tamiento con metformina, dado el riesgo de acidosis láctica más acentuado en estos\n    pacientes. Posteriormente, a pesar del tratamiento con dos antidiabéticos orales, si-\n    tagliptina 100 mg/día y repaglinida 1 mg cada 8 horas, persistían glucemias elevadas,\n    fundamentalmente preprandiales por lo que se añadió insulina basal. En este sentido,\n    se intentó simplificar lo máximo en el tratamiento insulínico, tanto por la imposibilidad\n    de autoinyección del paciente secundaria a la amaurosis como por la dificultad en la\n    comprensión del ajuste de dosis de insulina en función de glucemias por parte de la\n    cuidadora principal (madre). Además, se pautó tratamiento con coenzima Q 10 400 mg/día,\n    cápsulas de ácidos grasos omega 3 y L-carnitina 1 g al día.\n\n\n\n             Se derivó a Hematología para valoración de la posibilidad de trasplante de\n    células hematopoyéticas siendo desestimando el tratamiento. Posteriormente, se derivó\n    a Cirugía para valoración del trasplante hepático si bien también fue desestimado. En\n    esta situación sólo quedan medidas sintomáticas, ya que muchos pacientes progresan\n    a pseudoobstrucciones intestinales que obligan a nutrirlos vía parenteral. De momento,\n    el paciente que presentamos no ha llegado a esta situación.\n\n\n\n    Conclusiones\n             El síndrome de encefalopatía mitocondrial neurogastrointestinal con polineuro-\n    patía sensitivo-motora es una\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>MNGIE<|>EVENT<|>Mitochondrial neurogastrointestinal encephalopathy syndrome with sensory-motor polyneuropathy, a condition affecting patients' metabolism and gastrointestinal function)\n##\n(\"entity\"<|>L-CARNITINE<|>ORGANIZATION<|>L-carnitine is a treatment suggested for patients with mitochondrial disease, known for its safety and ability to correct underlying carnitine deficiency)\n##\n(\"entity\"<|>HEMATOLOGY<|>ORGANIZATION<|>Hematology department involved in evaluating the possibility of hematopoietic stem cell transplantation for patients)\n##\n(\"entity\"<|>SURGERY<|>ORGANIZATION<|>Surgery department involved in evaluating the possibility of liver transplantation for patients)\n##\n(\"entity\"<|>COENZYME Q10<|>ORGANIZATION<|>Coenzyme Q10 is a supplement suggested for patients, known for its role in energy production in cells)\n##\n(\"entity\"<|>PATIENT<|>PERSON<|>The patient discussed in the document suffers from mitochondrial disease and has undergone various treatments and evaluations)\n##\n(\"relationship\"<|>PATIENT<|>MNGIE<|>The patient is diagnosed with MNGIE, which affects their treatment options and health outcomes<|>8)\n##\n(\"relationship\"<|>PATIENT<|>L-CARNITINE<|>L-carnitine is suggested as a treatment for the patient to address carnitine deficiency<|>7)\n##\n(\"relationship\"<|>PATIENT<|>HEMATOLOGY<|>The patient was referred to Hematology for evaluation of potential hematopoietic stem cell transplantation<|>6)\n##\n(\"relationship\"<|>PATIENT<|>SURGERY<|>The patient was referred to Surgery for evaluation of potential liver transplantation<|>6)\n##\n(\"relationship\"<|>PATIENT<|>COENZYME Q10<|>Coenzyme Q10 is recommended for the patient as part of their treatment regimen<|>7)\n<|COMPLETE|>"}]}